A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.

David B. Miklos,Madan Jagasia,Hildegard T. Greinix,Bor-Sheng Ko,David A. Jacobsohn,Ahmad Mokatrin,Jason A. Dubovsky,Biljana Horn,Bernhard Hauns,Lori Styles,Mary E.D. Flowers

A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.

2017

David B. Miklos
Madan Jagasia
Hildegard T. Greinix
Bor-Sheng Ko
David A. Jacobsohn
Ahmad Mokatrin
Jason A. Dubovsky
Biljana Horn
Bernhard Hauns
Lori Styles
Mary E.D. Flowers

TPS7072Background: Chronic graft versus host disease (cGVHD) is a common complication of allogeneic stem cell transplantation, with pathophysiology involving alloreactive and dysregulated T and B c...

Keywords:

Physical therapy
Graft-versus-host disease
Placebo
Ibrutinib
Internal medicine
Cardiology
Medicine
new onset
Transplantation
Gastroenterology
Stem cell
Complication
Pathophysiology
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations